Intrinsic value of Dentsply Sirona - XRAY

Previous Close

$36.98

  Intrinsic Value

$36.32

stock screener

  Rating & Target

hold

-2%

Previous close

$36.98

 
Intrinsic value

$36.32

 
Up/down potential

-2%

 
Rating

hold

We calculate the intrinsic value of XRAY stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 8.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
  5.00
Revenue, $m
  4,193
  4,403
  4,623
  4,854
  5,097
  5,352
  5,619
  5,900
  6,195
  6,505
  6,830
  7,172
  7,530
  7,907
  8,302
  8,717
  9,153
  9,611
  10,091
  10,596
  11,125
  11,682
  12,266
  12,879
  13,523
  14,199
  14,909
  15,655
  16,437
  17,259
Variable operating expenses, $m
  3,649
  3,795
  3,948
  4,108
  4,277
  4,454
  4,640
  4,836
  5,041
  5,256
  4,748
  4,986
  5,235
  5,497
  5,772
  6,060
  6,363
  6,681
  7,015
  7,366
  7,734
  8,121
  8,527
  8,954
  9,401
  9,871
  10,365
  10,883
  11,427
  11,999
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  3,649
  3,795
  3,948
  4,108
  4,277
  4,454
  4,640
  4,836
  5,041
  5,256
  4,748
  4,986
  5,235
  5,497
  5,772
  6,060
  6,363
  6,681
  7,015
  7,366
  7,734
  8,121
  8,527
  8,954
  9,401
  9,871
  10,365
  10,883
  11,427
  11,999
Operating income, $m
  544
  608
  675
  746
  819
  897
  979
  1,064
  1,154
  1,249
  2,082
  2,186
  2,295
  2,410
  2,530
  2,657
  2,790
  2,929
  3,076
  3,230
  3,391
  3,561
  3,739
  3,926
  4,122
  4,328
  4,544
  4,772
  5,010
  5,261
EBITDA, $m
  1,460
  1,533
  1,609
  1,690
  1,774
  1,863
  1,956
  2,054
  2,157
  2,265
  2,378
  2,497
  2,622
  2,753
  2,890
  3,035
  3,187
  3,346
  3,513
  3,689
  3,873
  4,067
  4,270
  4,484
  4,708
  4,944
  5,191
  5,450
  5,723
  6,009
Interest expense (income), $m
  37
  89
  99
  109
  120
  132
  144
  157
  171
  185
  200
  216
  232
  250
  268
  287
  307
  328
  350
  374
  398
  424
  451
  479
  508
  540
  572
  607
  643
  681
  720
Earnings before tax, $m
  455
  509
  566
  625
  687
  753
  821
  893
  969
  1,048
  1,866
  1,953
  2,045
  2,142
  2,243
  2,350
  2,462
  2,579
  2,702
  2,831
  2,967
  3,110
  3,260
  3,417
  3,582
  3,756
  3,938
  4,129
  4,330
  4,540
Tax expense, $m
  123
  138
  153
  169
  186
  203
  222
  241
  262
  283
  504
  527
  552
  578
  606
  634
  665
  696
  730
  765
  801
  840
  880
  923
  967
  1,014
  1,063
  1,115
  1,169
  1,226
Net income, $m
  332
  372
  413
  456
  502
  549
  600
  652
  707
  765
  1,362
  1,426
  1,493
  1,564
  1,638
  1,715
  1,797
  1,883
  1,973
  2,067
  2,166
  2,270
  2,380
  2,494
  2,615
  2,742
  2,874
  3,014
  3,161
  3,314

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  10,891
  11,436
  12,007
  12,608
  13,238
  13,900
  14,595
  15,325
  16,091
  16,896
  17,740
  18,627
  19,559
  20,537
  21,564
  22,642
  23,774
  24,963
  26,211
  27,521
  28,897
  30,342
  31,859
  33,452
  35,125
  36,881
  38,725
  40,661
  42,694
  44,829
Adjusted assets (=assets-cash), $m
  10,891
  11,436
  12,007
  12,608
  13,238
  13,900
  14,595
  15,325
  16,091
  16,896
  17,740
  18,627
  19,559
  20,537
  21,564
  22,642
  23,774
  24,963
  26,211
  27,521
  28,897
  30,342
  31,859
  33,452
  35,125
  36,881
  38,725
  40,661
  42,694
  44,829
Revenue / Adjusted assets
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
Average production assets, $m
  5,145
  5,402
  5,672
  5,956
  6,254
  6,566
  6,895
  7,239
  7,601
  7,981
  8,380
  8,800
  9,239
  9,701
  10,187
  10,696
  11,231
  11,792
  12,382
  13,001
  13,651
  14,333
  15,050
  15,803
  16,593
  17,422
  18,294
  19,208
  20,169
  21,177
Working capital, $m
  797
  837
  878
  922
  968
  1,017
  1,068
  1,121
  1,177
  1,236
  1,298
  1,363
  1,431
  1,502
  1,577
  1,656
  1,739
  1,826
  1,917
  2,013
  2,114
  2,220
  2,331
  2,447
  2,569
  2,698
  2,833
  2,974
  3,123
  3,279
Total debt, $m
  1,826
  2,023
  2,230
  2,448
  2,676
  2,915
  3,167
  3,431
  3,708
  4,000
  4,306
  4,627
  4,964
  5,318
  5,690
  6,080
  6,490
  6,920
  7,372
  7,846
  8,344
  8,867
  9,417
  9,993
  10,599
  11,234
  11,902
  12,603
  13,339
  14,112
Total liabilities, $m
  3,943
  4,140
  4,347
  4,564
  4,792
  5,032
  5,283
  5,548
  5,825
  6,116
  6,422
  6,743
  7,080
  7,434
  7,806
  8,196
  8,606
  9,036
  9,488
  9,963
  10,461
  10,984
  11,533
  12,110
  12,715
  13,351
  14,019
  14,719
  15,455
  16,228
Total equity, $m
  6,949
  7,296
  7,661
  8,044
  8,446
  8,868
  9,312
  9,777
  10,266
  10,779
  11,318
  11,884
  12,479
  13,102
  13,758
  14,445
  15,168
  15,926
  16,722
  17,559
  18,436
  19,358
  20,326
  21,343
  22,410
  23,530
  24,707
  25,942
  27,239
  28,601
Total liabilities and equity, $m
  10,892
  11,436
  12,008
  12,608
  13,238
  13,900
  14,595
  15,325
  16,091
  16,895
  17,740
  18,627
  19,559
  20,536
  21,564
  22,641
  23,774
  24,962
  26,210
  27,522
  28,897
  30,342
  31,859
  33,453
  35,125
  36,881
  38,726
  40,661
  42,694
  44,829
Debt-to-equity ratio
  0.260
  0.280
  0.290
  0.300
  0.320
  0.330
  0.340
  0.350
  0.360
  0.370
  0.380
  0.390
  0.400
  0.410
  0.410
  0.420
  0.430
  0.430
  0.440
  0.450
  0.450
  0.460
  0.460
  0.470
  0.470
  0.480
  0.480
  0.490
  0.490
  0.490
Adjusted equity ratio
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  332
  372
  413
  456
  502
  549
  600
  652
  707
  765
  1,362
  1,426
  1,493
  1,564
  1,638
  1,715
  1,797
  1,883
  1,973
  2,067
  2,166
  2,270
  2,380
  2,494
  2,615
  2,742
  2,874
  3,014
  3,161
  3,314
Depreciation, amort., depletion, $m
  916
  925
  934
  944
  955
  966
  978
  990
  1,003
  1,016
  296
  311
  326
  343
  360
  378
  397
  417
  438
  459
  482
  506
  532
  558
  586
  616
  646
  679
  713
  748
Funds from operations, $m
  1,248
  1,297
  1,347
  1,401
  1,457
  1,515
  1,577
  1,642
  1,710
  1,781
  1,658
  1,737
  1,820
  1,906
  1,998
  2,093
  2,194
  2,299
  2,410
  2,526
  2,649
  2,777
  2,911
  3,053
  3,201
  3,357
  3,521
  3,693
  3,873
  4,063
Change in working capital, $m
  38
  40
  42
  44
  46
  48
  51
  53
  56
  59
  62
  65
  68
  72
  75
  79
  83
  87
  91
  96
  101
  106
  111
  117
  122
  128
  135
  142
  149
  156
Cash from operations, $m
  1,210
  1,257
  1,306
  1,357
  1,411
  1,467
  1,526
  1,589
  1,654
  1,723
  1,596
  1,672
  1,751
  1,835
  1,922
  2,014
  2,111
  2,212
  2,319
  2,431
  2,548
  2,671
  2,800
  2,936
  3,079
  3,229
  3,386
  3,551
  3,725
  3,907
Maintenance CAPEX, $m
  -173
  -182
  -191
  -200
  -210
  -221
  -232
  -244
  -256
  -269
  -282
  -296
  -311
  -326
  -343
  -360
  -378
  -397
  -417
  -438
  -459
  -482
  -506
  -532
  -558
  -586
  -616
  -646
  -679
  -713
New CAPEX, $m
  -245
  -257
  -270
  -284
  -298
  -313
  -328
  -345
  -362
  -380
  -399
  -419
  -440
  -462
  -485
  -509
  -535
  -562
  -590
  -619
  -650
  -683
  -717
  -753
  -790
  -830
  -871
  -915
  -960
  -1,008
Cash from investing activities, $m
  -418
  -439
  -461
  -484
  -508
  -534
  -560
  -589
  -618
  -649
  -681
  -715
  -751
  -788
  -828
  -869
  -913
  -959
  -1,007
  -1,057
  -1,109
  -1,165
  -1,223
  -1,285
  -1,348
  -1,416
  -1,487
  -1,561
  -1,639
  -1,721
Free cash flow, $m
  793
  818
  845
  873
  902
  933
  966
  1,000
  1,036
  1,074
  915
  957
  1,001
  1,046
  1,095
  1,145
  1,198
  1,254
  1,312
  1,374
  1,438
  1,506
  1,577
  1,652
  1,730
  1,813
  1,899
  1,990
  2,085
  2,185
Issuance/(repayment) of debt, $m
  184
  197
  207
  217
  228
  240
  252
  264
  277
  291
  306
  321
  337
  354
  372
  390
  410
  430
  452
  474
  498
  523
  549
  577
  605
  636
  668
  701
  736
  773
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  184
  197
  207
  217
  228
  240
  252
  264
  277
  291
  306
  321
  337
  354
  372
  390
  410
  430
  452
  474
  498
  523
  549
  577
  605
  636
  668
  701
  736
  773
Total cash flow (excl. dividends), $m
  977
  1,015
  1,052
  1,090
  1,131
  1,173
  1,218
  1,264
  1,314
  1,365
  1,221
  1,278
  1,338
  1,400
  1,466
  1,535
  1,608
  1,684
  1,764
  1,848
  1,937
  2,029
  2,127
  2,229
  2,336
  2,449
  2,567
  2,691
  2,821
  2,958
Retained Cash Flow (-), $m
  -332
  -347
  -365
  -383
  -402
  -422
  -443
  -466
  -489
  -513
  -539
  -566
  -594
  -624
  -655
  -688
  -722
  -758
  -796
  -836
  -878
  -922
  -968
  -1,016
  -1,067
  -1,120
  -1,177
  -1,235
  -1,297
  -1,362
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  645
  668
  687
  707
  728
  751
  774
  799
  825
  852
  682
  712
  743
  776
  811
  848
  886
  926
  968
  1,012
  1,059
  1,107
  1,159
  1,212
  1,269
  1,328
  1,390
  1,456
  1,524
  1,596
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  618
  611
  598
  582
  565
  545
  523
  499
  474
  447
  324
  304
  283
  261
  238
  215
  193
  171
  149
  129
  109
  92
  76
  62
  49
  39
  30
  23
  17
  12
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.

FINANCIAL RATIOS  of  Dentsply Sirona (XRAY)

Valuation Ratios
P/E Ratio 19.8
Price to Sales 2.3
Price to Book 1
Price to Tangible Book
Price to Cash Flow 15.1
Price to Free Cash Flow 19.5
Growth Rates
Sales Growth Rate 40.1%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 75%
Cap. Spend. - 3 Yr. Gr. Rate 4.5%
Financial Strength
Quick Ratio 18
Current Ratio 0
LT Debt to Equity 18.6%
Total Debt to Equity 18.9%
Interest Coverage 13
Management Effectiveness
Return On Assets 5.8%
Ret/ On Assets - 3 Yr. Avg. 6.6%
Return On Total Capital 6.5%
Ret/ On T. Cap. - 3 Yr. Avg. 7.4%
Return On Equity 8.2%
Return On Equity - 3 Yr. Avg. 10.8%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 53.4%
Gross Margin - 3 Yr. Avg. 55%
EBITDA Margin 20%
EBITDA Margin - 3 Yr. Avg. 19.6%
Operating Margin 12.1%
Oper. Margin - 3 Yr. Avg. 13.8%
Pre-Tax Margin 11.8%
Pre-Tax Margin - 3 Yr. Avg. 12.6%
Net Profit Margin 11.5%
Net Profit Margin - 3 Yr. Avg. 10.6%
Effective Tax Rate 2.3%
Eff/ Tax Rate - 3 Yr. Avg. 15.2%
Payout Ratio 15.1%

XRAY stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the XRAY stock intrinsic value calculation we used $3993.4 million for the last fiscal year's total revenue generated by Dentsply Sirona. The default revenue input number comes from 0001 income statement of Dentsply Sirona. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our XRAY stock valuation model: a) initial revenue growth rate of 5% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for XRAY is calculated based on our internal credit rating of Dentsply Sirona, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Dentsply Sirona.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of XRAY stock the variable cost ratio is equal to 87.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for XRAY stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Dentsply Sirona.

Corporate tax rate of 27% is the nominal tax rate for Dentsply Sirona. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the XRAY stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for XRAY are equal to 122.7%.

Life of production assets of 28.3 years is the average useful life of capital assets used in Dentsply Sirona operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for XRAY is equal to 19%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $6616.3 million for Dentsply Sirona - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 227.439 million for Dentsply Sirona is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Dentsply Sirona at the current share price and the inputted number of shares is $8.4 billion.

RELATED COMPANIES Price Int.Val. Rating
ALGN Align Technolo 222.77 271.47  sell
BIOL Biolase 1.27 0.32  str.sell
MLSS Milestone Scie 0.550 0.03  str.sell
DHR Danaher 101.65 86.30  hold
MMM 3M 204.91 232.48  hold

COMPANY NEWS

▶ Dentsply: 3Q Earnings Snapshot   [04:50PM  Associated Press]
▶ Stocks That Fell to 3-Year Lows in the Week of Nov. 2   [Nov-03-18 05:54PM  GuruFocus.com]
▶ Mawer Investment Management 3rd Quarter Newsletter   [Nov-02-18 01:35PM  GuruFocus.com]
▶ The 3 Worst-Performing Stocks in August   [11:18AM  Motley Fool]
▶ Stocks That Fell to 3-Year Lows in the Week of Aug. 17   [Aug-18-18 11:33AM  GuruFocus.com]
▶ Dentsply: 2Q Earnings Snapshot   [06:40AM  Associated Press]
▶ The 3 Worst Healthcare Stocks of 2018 (So Far)   [Jul-19-18 08:46AM  Motley Fool]
▶ The 5 Worst S&P 500 Stocks of 2018 (So Far)   [Jul-18-18 09:17AM  Motley Fool]
▶ These 3 Value Stocks Are Absurdly Cheap Right Now   [Jul-06-18 06:25AM  Motley Fool]
▶ Dentsply Sirona Declares Quarterly Cash Dividend   [Jun-26-18 05:30PM  GlobeNewswire]
▶ Is It Time To Buy DENTSPLY SIRONA Inc (NASDAQ:XRAY)?   [Jun-25-18 02:23PM  Simply Wall St.]
▶ Athenahealth, Exxon rise; Cognizant, Dentsply fall   [May-07-18 04:33PM  Associated Press]
▶ Dentsply: 1Q Earnings Snapshot   [05:04AM  Associated Press]
▶ Dentsply Sirona Reports First Quarter 2018 Results   [May-06-18 07:30PM  GlobeNewswire]
▶ Al Gore's Firm Is Buying These Two Stocks   [Apr-26-18 03:12PM  Barrons.com]
▶ Dentsply Sirona Declares Quarterly Cash Dividend   [Apr-25-18 05:15PM  GlobeNewswire]
▶ New Strong Sell Stocks for March 19th   [Mar-19-18 08:16AM  Zacks]
▶ Ruane Cunniff Comments on Dentsply Sirona   [Mar-06-18 05:42PM  GuruFocus.com]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.